OncLive® On Air

In today’s episode, we spoke with Alexander I. Spira, MD, PhD, FACP, FASCO. Dr Spira is co-director of the Virginia Cancer Specialists (VCS) Research Institute in Fairfax, director of the VCS Thoracic and Phase I Program, chief scientific officer of NEXT Oncology, and a clinical assistant professor at Johns Hopkins University in Baltimore, Maryland.
In our exclusive interview, Dr Spira discussed the significance of the December 2025 FDA approval of amivantamab and hyaluronidase-lpuj (Rybrevant Faspro), also known as subcutaneous amivantamab, for the treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC) across all approved indications for amivantamab-vmjw (Rybrevant). He noted key data from the pivotal phase 3 PALOMA-3 trial (NCT05388669), which showed that subcutaneous amivantamab combined with lazertinib (Lazcluze) had a more favorable safety profile compared with intravenous (IV) amivantamab plus lazertinib and was noninferior to the IV formulation in terms of efficacy. Dr Spira contextualized these trial findings within the larger EGFR-mutated NSCLC treatment paradigm and explained how this formulation of amivantamab addresses a previously unmet patient need.

In this podcast, experts Mark Agulnik, MD; Sandra D’Angelo, MD; Mrinal M. Gounder, MD; and Sujana Movva, MD; discuss the complexities of diagnosing epithelioid sarcoma (ES) in a timely manner and the importance of multidisciplinary care in treating this disease at all stages.

In today’s episode, we spoke with Nicholas Short, MD. Dr Short is an associate professor in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Dr Short discussed evolving factors at play for the treatment of patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). He also noted how the TKI ponatinib (Iclusig) stacks up against other TKIs for Ph-positive ALL, in addition to evolving approaches that incorporate treatments like blinatumomab (Blincyto).

Christopher Lieu, MD, expands on current treatment strategies and factors informing third-line sequencing decisions in mCRC.

In this podcast, experts Aakash Desai, MBBS, MPH; Ibiayi Dagogo-Jack, MD; and Patrick Forde, MBBCh, PhD, discuss how to decode the diagnosis of malignant pleural mesothelioma and review data to optimize frontline and subsequent treatment of this rare malignancy.